New oral arthritis drug tofacitinib 'as effective as TNF inhibitors'

Rheumatoid arthritis (RA) patients who fail to respond to traditional disease-modifying drugs could soon benefit from an alternative to injectable biologic agents.

Other JAK inhibitors are also in development for rheumatoid arthritis | SCIENCE PHOTO LIBRARY
Other JAK inhibitors are also in development for rheumatoid arthritis | SCIENCE PHOTO LIBRARY

Tofacitinib, the first in a new class of oral treatments known as Janus kinase (JAK) inhibitors, was accepted for regulatory approval yesterday. JAK inhibitors interrupt signalling downstream of multiple cytokines, rather than blocking one cytokine at a time in the manner of tumour necrosis factor (TNF) inhibitors.

‘Impressive drug’

In the phase 3 ORAL trial programme involving more than 4000 patients with moderate to severe active RA, tofacitinib consistently reduced signs and symptoms of RA. Adverse events, including infections and reduced neutrophil counts, were generally mild to moderate.

"This looks like an impressive drug. This is some of the most important phase 3 data we’ve seen," said Paul Emery, Professor of Rheumatology and Head of the Academic Unit of Musculoskeletal Medicine at the University of Leeds.

Promising results

In one 12-month study ('ORAL Standard'), investigators randomised 717 patients to receive tofacitinib (5mg or 10mg twice daily), adalimumab (40mg subcutaneously every two weeks) or placebo, in addition to methotrexate. Although the study was not designed as a head-to-head superiority or non-inferiority comparison, the data for tofacitinib and adalimumab were numerically similar for all outcomes.

After 6 months, ACR20 response rates were 51.5% and 52.6% for tofacitinib 5mg and 10mg, respectively, compared with 47.2% for adalimumab and 28.3% for placebo. Serious adverse events were more common with tofacitinib than adalimumab, although most adverse events were mild.

Tofacitinib, previously known as tasocitinib, has been developed by Pfizer. It is also being tested in psoriasis, inflammatory bowel disease and renal transplantation.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted
MIMSconnect

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)